A detailed history of Susquehanna International Group, LLP transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 73,748 shares of VERV stock, worth $546,472. This represents 0.0% of its overall portfolio holdings.

Number of Shares
73,748
Previous 192,406 61.67%
Holding current value
$546,472
Previous $938,000 62.05%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.4 - $7.86 $522,095 - $932,651
-118,658 Reduced 61.67%
73,748 $356,000
Q2 2024

Aug 15, 2024

BUY
$4.76 - $12.79 $665,838 - $1.79 Million
139,882 Added 266.32%
192,406 $938,000
Q1 2024

May 07, 2024

SELL
$10.81 - $17.96 $823,635 - $1.37 Million
-76,192 Reduced 59.19%
52,524 $697,000
Q4 2023

Feb 14, 2024

BUY
$8.84 - $18.7 $845,006 - $1.79 Million
95,589 Added 288.55%
128,716 $1.79 Million
Q3 2023

Nov 14, 2023

BUY
$11.42 - $20.82 $140,054 - $255,336
12,264 Added 58.78%
33,127 $439,000
Q2 2023

Aug 11, 2023

SELL
$13.34 - $19.9 $1.3 Million - $1.94 Million
-97,575 Reduced 82.38%
20,863 $391,000
Q1 2023

May 16, 2023

BUY
$14.3 - $24.01 $643,771 - $1.08 Million
45,019 Added 61.32%
118,438 $1.71 Million
Q4 2022

Feb 14, 2023

SELL
$17.85 - $40.7 $428,275 - $976,515
-23,993 Reduced 24.63%
73,419 $1.42 Million
Q3 2022

Nov 14, 2022

BUY
$15.63 - $41.49 $1.2 Million - $3.19 Million
76,802 Added 372.64%
97,412 $3.35 Million
Q2 2022

Aug 15, 2022

SELL
$11.14 - $23.17 $292,391 - $608,142
-26,247 Reduced 56.02%
20,610 $315,000
Q1 2022

May 16, 2022

SELL
$20.92 - $39.36 $217,672 - $409,540
-10,405 Reduced 18.17%
46,857 $1.07 Million
Q4 2021

Feb 14, 2022

BUY
$31.94 - $54.82 $1.83 Million - $3.14 Million
57,262 New
57,262 $2.11 Million
Q3 2021

Nov 15, 2021

SELL
$46.0 - $73.99 $1.31 Million - $2.11 Million
-28,525 Closed
0 $0
Q2 2021

Aug 11, 2021

BUY
$31.92 - $60.25 $910,518 - $1.72 Million
28,525 New
28,525 $1.72 Million

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $444M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.